CSTL Castle Biosciences

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been named a Houston Chronicle Top Workplace for the second year in a row. More than 70,000 employees from 4,966 companies in the Houston metro area participated in the nomination process, but only 200 companies were named as 2022 Top Workplaces, including Castle.

“One of Castle’s foundational guideposts includes attracting and cultivating exceptional employees, and we believe that our incredibly talented team is what gives us our competitive edge,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We are thrilled to once again have been named a Top Workplace in Houston and believe this award reflects our strong culture, people-first mindset and importantly, our dynamic and committed employees who are helping us meaningfully impact patient care.”

The Top Workplaces program starts with capturing employee feedback on what matters most about a company’s culture through an anonymous survey. The survey measures fifteen drivers of company culture that are critical to an organization’s success, as well as other insights related to a company’s leadership and employee engagement.

Earlier this year, Castle also received several Top Workplaces Culture Excellence Awards, which nationally recognized the Company for excelling in the following areas of its workplace culture:

  • Innovation: for creating a culture where new ideas are encouraged, which helps employees to reach their full potential and benefits performance.
  • Employee Appreciation: for believing in the self-sustaining performance and positivity boost that results from genuine employee appreciation.
  • Compensation & Benefits: for providing packages their employees believe are fair for the work being done and compared to others in the industry.
  • Employee Well-Being: for putting the health and wellness of employees at the center of their workplace culture.
  • Professional Development: for placing a special focus on developing their employees' careers and enabling their people to grow professionally.
  • Leadership: for leaders who inspire confidence in their employees and in the direction of the company.
  • Purpose & Values: for successfully communicating the company mission and integrating those aspirations into the culture.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit and connect with us on , , and .

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

EN
14/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Castle Biosciences Enters Collaboration and License Agreement with Sci...

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (“SciBase”) utilizing SciBase’s Electrical Impedance Spectroscopy technology which include...

 PRESS RELEASE

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Particip...

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The panel will ...

 PRESS RELEASE

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored ...

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguish...

 PRESS RELEASE

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improv...

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients FRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 Ameri...

 PRESS RELEASE

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare ...

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at . A replay of the webcast will be a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch